BDTX vs. IOVA, SANA, XNCR, AVXL, OCS, VIR, KURA, AVBP, SEPN, and RZLT
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Iovance Biotherapeutics (IOVA), Sana Biotechnology (SANA), Xencor (XNCR), Anavex Life Sciences (AVXL), Oculis (OCS), Vir Biotechnology (VIR), Kura Oncology (KURA), ArriVent BioPharma (AVBP), Septerna (SEPN), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs. Its Competitors
Iovance Biotherapeutics (NASDAQ:IOVA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Black Diamond Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -161.44%. Black Diamond Therapeutics' return on equity of 12.70% beat Iovance Biotherapeutics' return on equity.
Iovance Biotherapeutics presently has a consensus price target of $11.90, suggesting a potential upside of 484.77%. Black Diamond Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 252.11%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than Black Diamond Therapeutics.
Iovance Biotherapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.
Black Diamond Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Iovance Biotherapeutics had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 2 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.34 beat Iovance Biotherapeutics' score of 0.72 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Summary
Black Diamond Therapeutics beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 9/25/2025 by MarketBeat.com Staff
Free BDTX Stock Alerts